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Abstract
Autophagy is the process by which lysosomes degrade and recycle damaged proteins and
organelles in order to promote cell survival under situations of nutrient deprivation and
homeostatic stress. Studies in the Lounsbury Lab have identified threonyl-tRNA synthetase
(TARS) as a potential regulator in the autophagy pathway. This study tests the hypotheses that
TARS independently inhibits the process of autophagy within human ovarian cancer cells and
that blocking TARS signaling increases markers of autophagy within tumors in a mouse model of
ovarian cancer. Ovarian cancer cells were cultured and transfected with siRNA to reduce TARS
levels and quantitative Western blotting was employed to test the effects of TARS knockdown
during amino acid starvation or mTOR inhibition. Changes were detected using antibodies
against TARS, the positive autophagy markers p-AMPK and p-ULK, and the protein p62. TARS
knockdown by siRNA was successful (p<0.0001) and TARS inhibition resulted in increased
levels of p-AMPK (p=0.0007) and p-ULK (p=0.003). To assess in vivo effects of TARS activity
on autophagy, mice were injected subcutaneously with ID-8 ovarian cancer cells. After three
weeks, the animals were treated three times per week with either vehicle control or the TARS
inhibitor BC194. Tumor sections were analyzed by immunohistochemistry to detect TARS,
autophagy, and inflammatory markers. Tumors treated with BC194 were larger and showed
increased levels of TARS. The results of this study have strong implications for the potential to
identify a novel therapeutic target in ovarian cancer treatment.

Introduction
Aminoacyl-tRNA synthetases
The canonical function of aminoacyl-tRNA synthetases (ARSs) is in protein translation,
where the enzymes catalyze the attachment of individual amino acids to their corresponding
tRNAs (Park, Ewalt, & Kim, 2005). Once the tRNA has been “charged” with its appropriate
amino acid according to the genetic code, the amino acid can be added to the growing protein
peptide. The presence of ATP is required for the ARS to recognize the proper amino acid and
perform the aminoacylation (Figure 1). As a consequence of their function, ARS enzymes are
able to sense both the presence of energy in the form of ATP as well as the availability of amino
acids within the cell. Previously thought of as only a “housekeeping enzyme,” ARS enzymes
have recently been found to play a role in a variety of other cellular functions.
Threonyl-tRNA synthetase (TARS) catalyzes the attachment of threonine to its cognate
tRNA. Previous studies in the Lounsbury lab have concluded that TARS exerts angiogenic
activity and stimulates endothelial cell migration in both in vivo and in vitro models using human
umbilical vein endothelial cells (Williams, Mirando, Wilkinson, Francklyn, & Lounsbury, 2013).
Both angiogenic and metastatic capabilities contribute to the malignancy and poor prognosis
associated with human ovarian cancer. This conclusion led to further studies investigating the
role of TARS in ovarian cancer tumor progression. Data from the Lounsbury lab offered the first
positive correlation between increasing disease stage and TARS expression in human ovarian
cancer cells (Wellman et al., 2014). Though overexpression of TARS was correlated with
increased cancer aggression, Cox proportional hazard models showed that TARS expression
within the tumor was inversely correlated with mortality in late stage disease (Wellman et al.,
2014). The mechanism by which TARS is interacting with the cancer cells to create these effects

is still largely unknown, though autophagy-mediated changes in the tumor microenvironment
have been observed in ovarian and breast cancer models (Mowers, Sharifi, & Macleod, 2017).
The current research interest of the Lounsbury lab is the role of TARS in autophagy. The
goal of this study was to test the hypotheses that TARS independently inhibits the process of
autophagy within human ovarian cancer cells and that blocking TARS signaling increases
markers of autophagy within tumors in a mouse model of ovarian cancer.

Figure 1: Canonical Function of Aminoacyl-tRNA Synthetase. Aminoacyl-tRNA synthetases (ARSs)
play an integral role in the conversion from genetic code to functional protein. ARSs are ATP-dependent
enzymes which catalyze the attachment of amino acids to the proper tRNA. The amino acid is then added to
the growing protein peptide (from Rajendran et al., 2018).

Autophagy Signaling
Autophagy is the process by which cells selectively digest and recycle internal organelles
and structures. Autophagy is activated in response to low nutrient availability and other forms of
stress such as oxygen deprivation, with the products of autophagy-mediated degradation
including the building blocks of protein synthesis (Behrends, Sowa, Gygi, & Harper, 2010).
Autophagy is a complex system regulated by a network of over 30 autophagy-related gene
(ATG) proteins (Xu et al., 2019). There are several types of autophagy that are known and
understood. Microautophagy is the process by which lysosomes engulf cytoplasmic materials via
invagination of the lysosomal membrane. Chaperone-mediated autophagy is achieved by
chaperones, co-chaperones, and a lysosomal-associated membrane protein. Macroautophagy, the
focal point of this paper which will hereby be referred to as “autophagy,” is characterized by the
formation of a double-membrane organelle called an autophagosome (Jiang & Mizushima,
2014). Formation of the autophagosome is the rate-limiting step in the initiation of autophagy
and requires more than 20 different autophagy-related proteins (Meijer & Codogno, 2008).
Autophagosomes collect both stable and unstable cellular contents and then fuse with lysosomes,
forming autophagolysosomes (Figure 2). It is within these autophagolysosomes that degradation
and recycling occurs (White, Mehnert, & Chan, 2015).
Autophagy is a sort of double-edged sword within human cell lines. When a tumor is
initially emerging, autophagy has a preventative effect against development and growth of the
cancer. Cells utilize lysosomal degradation to prevent the accumulation of damaged organelles
and the proliferation of mutated DNA. Thus, early in cancer development, autophagy works in
conjunction with DNA repair as a sort of gatekeeping mechanism to ensure that everything is in
order. However, once a tumor has developed and established itself within the tissue, the cancer
cells exploit autophagy for their own protection (Jiang & Mizushima, 2014). During scenarios of

extreme nutrient deprivation and oxidative stress—such as radiation and chemotherapy—the
cancer cells are almost entirely reliant on autophagy-mediated recycling to sustain baseline
function (Kung, Bergenstock, Balaburski, Budina, & Murphy, 2012). Upregulation of autophagy
allows cancer cells to survive under conditions which would otherwise result in their
degradation, thereby promoting cancer survival and proliferation.

Figure 2: Process of Macroautophagy. Nutrient deprivation and stress result in damaged organelles,
proteins, and cytoplasmic components being engulfed in a double membrane autophagosome. The
autophagosome then fuses with a lysosome to form an autophagolysosome, where these components are
degraded and recycled to be used for metabolism and energy (from White et al., 2015).
.
Nutrient deprivation is the most well understood inducer of autophagy through a pathway
that includes AMP-activated protein kinase (AMPK) and UNC-51 like activating autophagy
kinase (ULK1). AMPK is an enzyme with the ability to sense the AMP:ATP ratio within the cell
and thus monitor energy availability (Kung et al., 2012). When the cell is deprived of nutrients
and energy stores are low, AMPK is activated via phosphorylation. Phospho-AMPK (p-APMK)
induces autophagy indirectly via inhibition of mechanistic target of rapamycin (mTOR). mTOR
is a known and established inhibitor of autophagy which is activated only in the presence of
amino acids, ensuring that autophagy is inhibited only if the cell has ample materials available

for metabolism (Meijer, Lorin, Blommaart, & Codogno, 2015). p-AMPK can also induce
autophagy directly via phosphorylation of ULK1.
The ULK1 complex contains the protein kinases ULK1/2 and is essential for the
formation of the autophagosome and the induction of autophagy (Meijer et al., 2015). p-AMPK
and mTOR both phosphorylate the ULK1 complex with antagonistic effects on autophagy
induction. While ULK1 phosphorylation by p-AMPK induces autophagy via formation of the
autophagosome, ULK1 phosphorylation by mTOR occurs at a different site and inhibits
autophagy via dissociation and inactivation of the ULK1 complex (Meijer et al., 2015).
The ubiquitin- and LC3-binding protein p62 is commonly used as an autophagy-related
marker (Xu et al., 2019). p62 plays a critical role in the formation of intracellular protein
aggregates which are subsequently engulfed by the autophagosome (Komatsu et al., 2007). p62
itself is engulfed and degraded during the autophagic process after forming a complex with
ubiquitinated proteins and LC3 (Xu et al., 2019). Inhibition of autophagy has been associated
with accumulation of p62 within the cytoplasm (Xu et al., 2019).
The proposed hypothesis predicts a role for TARS-mediated autophagy inhibition that is
independent of mTOR (Figure 3). The positive autophagy markers p-AMPK and p-ULK are
used as a proxy to quantify the induction/inhibition of autophagy within the cultured cell lines.

Figure 3: Proposed Autophagy Pathway. mTOR inhibits autophagy via phosphorylation and
dissociation of ULK1. AMPK initiates autophagy via phosphorylation and activation of ULK1. It is
proposed that TARS inhibits autophagy independently of mTOR via AMPK and ULK1 inhibition (from
Andrews et al, 2018).

Autophagy and Ovarian Cancer
Because of the complicated interaction of pathways involved in autophagy signaling,
dysregulation of these pathways has been implicated in the etiologies of several human diseases
including type 2 diabetes, heart and liver disease, lysosomal storage disorders, and cancer
(Meijer et al., 2015). The American Cancer Society reported in 2009 that ovarian carcinoma was
the gynecologic malignancy with the highest case-to-fatality ratio, with 69% of all diagnosed
patients dying of the disease (Lengyel, 2010). Epithelial ovarian cancer owes its high mortality
rate to several factors. There is a lack of effective testing to detect early stage disease, especially
in pre-menopausal women, resulting in late stage diagnosis for most patients (Wellman et al.,
2014). Coupled with this late stage diagnosis is a vast majority of patients presenting with
already widely metastatic disease (Lengyel, 2010). Finally, mortality is associated with a high
instance of tumor relapse following anticancer therapies. Tumor progression and relapse have
largely been contributed to cancer stem cells which retain the ability to survive nutrient
starvation and treatment with chemotherapy (Pagotto et al., 2017). This resistance to
chemotherapy has been associated with autophagy activation within malignant cells.
Studies suggest a role for autophagy in several steps of the metastatic cascade. The
metastatic cascade is the process by which a cancer physically leaves the primary site to establish
and grow at a secondary site. The cascade occurs in stages: local invasion at a primary site,
intravasation to the blood or lymphatic system, survival in circulation, extravasation to the
secondary site, and survival and growth at the secondary site (Mowers et al., 2017). Movement
in every stage of the metastatic cascade subjects the cancer to cellular stressors such as nutrient
deprivation, hypoxia, and lack of physical support. Increased autophagy has been observed in
cancer stem cells, assisting the epithelial-mesenchymal transition and allowing the cancer to
survive in a changing microenvironment (Mowers et al., 2017). Autophagy has also been found

to play a key role in modulating tumor dormancy and drug resistance (Mowers et al., 2017). It is
possible that combining autophagy inhibition with classical anticancer therapies will target the
epithelial ovarian cancer stem cell population, overcoming the current treatment limits (Pagotto
et al., 2017). Additional information about the cellular mechanisms and regulation of autophagy
must be obtained before assessing the validity of any such therapy options.

TARS and Autophagy
The proposed involvement of TARS in the autophagy pathway is the basis for this study.
Previous studies have shown that knockdown of genes encoding ARS enzymes rescued animals
from hypoxia-induced death (Anderson, Mao, Scott, & Crowder, 2009). This suggests that
decreasing ARS expression allows cells to better perform the autophagic processes required for
survival. Studies in the Lounsbury lab have concluded that TARS, but not seryl- or tyrosyl-tRNA
synthetase, is overexpressed in ovarian cancer cells (Wellman et al., 2014). We predicted that
TARS inhibits autophagy independently of mTOR via direct interaction with the ULK1 complex
and AMPK. This prediction was tested by reducing TARS levels using siRNA knockdown in
cultured ovarian cancer cells and by examining ovarian tumor sections from mice that had been
treated with a TARS inhibitor. In both systems, antibodies were utilized to quantify the amount
of p-ULK and p-AMPK present in cell lysates or tissue sections. This quantification was then
used as a proxy to determine the levels of autophagy occurring within the cell under normal
conditions and in the absence of TARS.
This study hopes to elucidate the functions of autophagy in tumor cells so that autophagy
inhibitors may be used in the clinical setting to treat or prevent the spread of metastatic cancer.
ARS enzymes have already been identified as potential drug targets for a variety of human
maladies (Rajendran, Kalita, Shukla, Kumar, & Tripathi, 2018). Due to the structural similarity

of ARS enzymes in different organisms, the potential for testing the effects of ARS inhibition is
promising in non-human models. Potential targets of autophagy induction or inhibition have
been identified in many different disease states (Galluzzi, Pedro, Levine, Green, & Kroemer,
2017) (Figure 4). Understanding the role of TARS in cancer cell autophagy will contribute to the
greater understanding of using ARS enzymes as pharmaceutical targets in the treatment of cancer
and other illnesses.

Figure 4: Interaction of known autophagy activators and inhibitors with the autophagy
induction sequence. Current pharmacological interventions to inhibit or enhance autophagy at the
initiation, nucleation, elongation, fusion, or degradation phases (from Galluzzi et al., 2017).

Methods
To test the hypothesis that TARS independently inhibits the process of autophagy within human
ovarian cancer cells, quantitative Western blotting using primary antibodies against autophagy
markers was employed.
Western Blotting
SKOV3 cells: The cells used in this experiment were SKOV3 human ovarian cancer cells.
These cells were cultured in McCoys media + 10% fetal bovine serum and passaged using
trypsin to generate 1 10 cm plate/condition. Cells were grown in an incubator at 37◦C with 5%
CO2.
Cell Transfection: Cells were transfected one day after passage. For siRNA, cells were
exposed to TARS siRNA (siTARS) or non-targeting control siRNA (siControl) using the
siTRAN™ protocol. Cells were incubated for 4-6 hours and then the media was changed to
antibiotic-free McCoys. Cells were then harvested approximately 48 hours after transfection.
Cell Treatments: One day after transfection, the cells were treated with either DMSO
(vehicle control), amino acid starvation media (EBSS), or Torin1 (mTOR inhibitor). Each of the
experimental treatments were performed for siControl and siTARS so that the results of the
treatments could be confidently attributed to the treatments themselves.
Protein Extracts: Following treatments (16 hr), cells were harvested to make protein
extracts using the protocol by Williams et al. (Williams et al., 2013). Briefly, the plates were
washed with phosphate buffered saline and modified RIPA buffer was added to each plate. The
contents of the plates were then scraped and transferred into a correspondingly labeled microfuge
tube and frozen at -80◦C. To ensure equal protein loading, 2 μl from each sample was used to
determine protein concentration using the Bradford protein assay.

SDS-PAGE and Western Blot: Protein samples (10 μg) were boiled in Laemmli sample
buffer and separated by 8% SDS-PAGE. Molecular weights of bands were determined using a
pre-stained molecular weight marker. Proteins were transferred to nitrocellulose (blot) and
blocked in 3% milk in Tris-buffered saline/tween-20 (TBST). The blots were exposed overnight
to primary antibodies diluted 1:1000 in 3% BSA/TBST + 0.1% azide. Primary antibodies
supplied by GeneTex and Cell Signaling Technology included: GTX116359 Rab anti-TARS,
CS21285 Rab anti-β-tub, CST2535 Rab anti-p-AMPK, CST6888 Rab anti-p-ULK1 (3757), and
CST5114 Rab anti-SQSTM1/p62. After incubation, the primary antibody was recovered, and the
blots were washed several times with TBST. Secondary antibody (HRP-Goat-anti-rabbit IgG,
Jackson Laboratories) was applied at a dilution of 1:5000 in 3% BSA/TBST. After thorough
washing with TBST, blots were developed using chemiluminescence (Clarity™) (Figure 5).
Imaging and quantification of blots were performed using the Biorad AI600.
Statistical Analysis: Western blot band pixel intensities were determined using the
software on the Biorad AI600 using rolling ball background subtraction. Statistical analysis of
the results was generated by Graphpad/Prism using 2-way ANOVA for multiple comparisons.

Figure 5: Interaction of primary and secondary antibodies with ClarityTM chemiluminescence.
The primary antibody specific to a single target protein binds to the protein on the gel. Species-specific
secondary antibody recognizes and binds to the primary antibody. The horse radish peroxidase enzyme
activity conjugated to the secondary antibody converts the applied chemiluminescence substrate into
product and emitted light, which is detected by the Bio-Rad AI600 (from Bio-Rad ClarityTM and
Clarity MaxTM Western ECL Blotting Substrates).

To test the hypothesis that blocking TARS signaling increases markers of autophagy within
tumors in a mouse model of ovarian cancer, immunohistochemistry using primary antibodies
against autophagy markers was employed.
Immunohistochemistry
Source of Ovarian Tumor Sections: Note, no animals were used specifically for this
study, only tumor sections from a previous study. To generate tumor sections for this study,
female mice were anesthetized and subcutaneously injected in the flank with ID8 mouse ovarian
cancer cells. Three weeks following initial injection, animals were injected intraperitoneally with
either vehicle control or TARS inhibitor BC194 (2 mg/kg) three times per week for four weeks.
Tumors were resected and embedded in paraffin (Figure 6). Tumor sections (10 μm) were
transferred to slides for antibody staining.

Figure 6: Resected flank ID8 ovarian cancer tumors treated with vehicle control or BC194.
Female mice were injected in the bilateral flanks with an equal number of ID8 ovarian cancer
cells. After treatments 3x per week for 4 weeks, mice were sacrificed and tumors were resected
for fixation.

Antibody staining of sections: The slides were dewaxed and rehydrated using xylenes
followed by decreasing concentrations of ethanol. After rinsing in water, the samples were
unmasked in plastic Coplin jars using DAKO Antigen Retrieval solution at 98 ̊C for 20 minutes
and subsequently allowed to cool at room temperature for 20 minutes. The slides were washed
three times with deionized water. Endogenous peroxide activity was quenched with peroxidase
block (4ml 30% H2O2 + 36ml methanol per Coplin jar) for 10 minutes. The slides were washed
once with deionized water and then for 5 minutes in PBS. All slides were blocked with two drops
of Vector Normal Horse serum, except the F4/80 for which Normal Goat serum was used. The
slides were left at room temperature for one hour under parafilm. Excess solution was drained
from the slides.
Antibodies: Primary antibodies were: GTX116359 Rab anti-ThrRS (TARS) (1:200), Cell
signaling rab anti-P-ULK1 (S555) (1:200), Cell signaling rab anti-P-AMPK (1:200), and AbD
MCA497GA Rat anti-F4/80 (1:250) in 3% BSA /0.2% TX-100/ PBS. Antibodies were applied to
the sections, they were covered with parafilm, and then they were incubated for 24 hours in a
humidity box at 4 ̊C. After incubation, slides were washed with PBS 3 x 5 minutes while
rocking. Excess solution was blotted off. Secondary antibodies were applied (2 drops) using
Vector Labs # MP-7401 ImmPRESS Polymer HRP horse anti-rabbit IgG or goat anti-rat IgG for
F4/80. Slides were incubated for one hour at room temperature in the dark.
Developing: Slides were developed with ImmPACT developer (36 μl DAB
(diaminobenzidine)/ml diluent) 10 min and then counterstained with filtered Mayer’s
hematoxylin for one minute. Slides were dehydrated through increasing concentrations of
ethanol followed by xylenes and mounted with Cytoseal-60. Images were collected on an
Olympus BX50 Light Microscope in the Microscopy Imaging Center.

Results
To determine whether reducing TARS levels results in the induction of autophagy,
SKOV3 cells were incubated with either non-targeting control siRNA (siCon) or TARS-specific
siRNA (siTARS). Cells were then treated with either the mTOR inhibitor Torinn1 or with
starvation media (EBSS) to stimulate autophagy. Western blot of the cell lysates was performed
to detect TARS, p-AMPK, p-ULK1, p62, and β-tubulin.
Bands shown in Figure 7a show the predicted molecular mass of TARS is 83 kDa, the
predicted molecular mas of p-ULK phosphorylated at the Serine 757 site is 140-150 kDa, the
predicted molecular mass of p-AMPK phosphorylated at the Threonine 173 site is 62 kDa, and
the predicted size of p62 is 62 kDa (Figure 7A). Protein loading was determined by levels of βtubulin at 50 kDa and quantification was normalized to the intensity of the β-tubulin band.
Western blot quantification of TARS shows successful knockdown of TARS by siRNA
(p<0.0001), with an average knockdown of 80% (Figure 7B). Successful siRNA knockdown
allows the results to be attributed to reduced TARS levels alone without needing to account for
the effect of treatment with siRNA. In the control treatment, TARS knockdown by siRNA
resulted in increased levels of p-ULK (p=0.003) and p-AMPK (p=0.0007) compared to siControl
(Figure 7B). This suggests that TARS inhibition induces autophagy. In the Torin1 treatment,
levels of p-ULK were slightly elevated in the siTARS group compared to siControl, though this
result was not significant (p=0.07) (Figure 7B). There was no effect of siTARS on levels of pAMPK or p62 in the Torin1 treatment. Within the siControl group, there was a significant
increase in p-ULK (p=0.03) and p-AMPK (p=0.0095) in the EBSS treatment when compared to
the control treatment (Figure 7B), confirming that amino acid starvation induces autophagy in
healthy cells. There was no effect of siRNA transfection or treatment on levels of p62.
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Figure 7: The effects of TARS knockdown on expression of p-ULK, TARS, p-AMPK, and p62
under control, Torin1, and EBSS treatments. A, Western blot of SKOV3 cells exposed to either
non-targeting control siRNA (siCon) or TARS-specific siRNA (siTARS) treated with primary
antibodies against p-ULK, TARS, p-AMPK, β-tubulin, and p62. Lanes 1, 4 are control treatment;
lanes 2, 5 are Torin1 (mTOR inhibition) treatment; lanes 3, 6 are EBSS (amino acid starvation)
treatment. β-tubulin used as loading control. B, Western blot quantifications normalized against
loading control. Columns and error bars represent mean and standard deviation. ****p<0.0001;
***p=0.0007; **p=0.003. n=4.

To determine if loss of TARS also affects autophagy in vivo, the effects of the TARS
inhibitor BC194 on the growth and autophagy of ovarian cancer flank tumors was measured.
Mouse flank tumors treated with BC194 appeared larger in size than tumors treated with vehicle
control (Figure 8A). This suggests that TARS enzyme inhibition allowed the cancer cells to
propagate more effectively than cells with normal levels of TARS enzymatic activity. TARS
staining increased with BC194 treatment compared to vehicle control (Figure 8A), representing
a potential compensatory effect of enzyme inhibition. Both vehicle control and BC194
treatments showed macrophage invasion with F4/80 staining (Figure 8A). Tumors treated with
BC194 had elevated levels of active site-phosphorylated ULK and AMPK compared to control
(Figure 8B), suggesting an induction of autophagy, although these data were more variable.
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Figure 8: The effect of TARS enzyme inhibition on tumor pathology, expression of TARS, pULK, and p-AMPK, and macrophage infiltration. Tumors treated with vehicle control or
TARS enzymatic activity inhibitor BC194. A, sections of tumor gross pathology, histology with
no primary antibody, and immunohistochemistry staining using primary antibodies against TARS
and F4/80, a mouse macrophage marker, n=8. B, antibody staining against ULK1 and the
activating phospho-sites of ULK1 and AMPK, n=2.

Discussion
The overall goal of this study was to test the hypothesis that TARS is a negative regulator
of autophagy, thus reducing TARS expression/activity would result in the induction of
autophagy. Successful TARS knockdown of 80% using siRNA allowed the obtained results to be
attributed to the individual treatments (Figure 7B). Increased levels of p-ULK and p-AMPK in
the siTARS group compared to the siControl group suggest that TARS inhibition results in
induction of autophagy (Figure 7B). The hypothesis that TARS inhibits autophagy is supported
by these results. If p62 was involved in the TARS signaling pathway, it would be predicted that
levels of p62 decrease with autophagy induction, as p62 is degraded in the autophagic process.
Because there was no effect of TARS knockdown on levels of p62, it is possible that this
degradation product may be a part of a separate, unrelated autophagy mechanism (Figure 7B). If
TARS-mediated autophagic inhibition occurs independently of the mTOR complex, it would be
predicted that levels of p-ULK and p-AMPK would be greater in the siTARS Torin1 treatment
than in the siControl Torin1 treatment. Levels of p-ULK and p-AMPK appear to be slightly
elevated in the siTARS treatment compared to siControl, but these results were not significant
(Figure 7B). The hypothesis that TARS inhibits autophagy independently of mTOR was not
supported by the data. Amino acid starvation should induce autophagy in healthy cells and thus
was used as a positive control. EBSS treatment did result in significantly increased levels of pULK and p-AMPK in the siControl group compared to the control treatment (Figure 7B). There
did not appear to be a combination effect of TARS inhibition and amino acid starvation, as there
was no increase in positive autophagy markers between the control and EBSS treatments in the
siTARS group (Figure 7B). This may be because TARS is acting as the sensor of energy
availability within the cell and thus when TARS is inhibited the cell can no longer react as
efficiently to low nutrient levels.

In the in vivo mouse tumor study, treatment with the Borrelidin derivative BC194
resulted in tumors that appeared larger in size and possibly had more extensive blood vessel
growth (Figure 8A). These results were unexpected because previous work by the Lounsbury lab
suggested that TARS promotes angiogenesis. It is possible that autophagy inhibition is the
mechanism by which TARS produces these effects and that the increased size of tumors is
primarily due to infiltrating macrophages. BC194 treatment resulted in increased levels of TARS
staining in mouse tumor models of ovarian cancer (Figure 8A). This result may represent a
compensation effect whereby TARS enzyme inhibition results in increased expression of TARS.
Such a compensation effect has been documented in the use of phosphatidylinositol 3-kinase
(PI3K) enzyme inhibitors in the treatment of non-small cell lung cancer. Response to inhibition
of class IA PI3K enzymes suggested that PI3K isoforms may functionally compensate for one
another to limit the efficacy of single agent treatments (Stamatkin, Ratermann, Overley, &
Black, 2015). TARS inhibition did not dramatically effect tumor macrophage infiltration
compared to vehicle control, although it was slightly elevated (Figure 8A). Tumor-associated
macrophages are always abundant in malignant tumors. These macrophages promote
angiogenesis, extravasation, and suppression of antitumor immune mechanisms (Yang, Mckay,
Pollard, & Lewis, 2018). For these reasons, it would be predicted that more aggressive and larger
tumors would show increased levels of macrophage staining. Qualifying the degree of antibody
stain on a tumor section is very difficult and quite subjective. It is possible that there are different
levels of staining between the control and BC194 tumors that cannot be detected. It is also
possible that the tumors were not able to grow for long enough to see the changes in macrophage
infiltration associated with increased aggressiveness and size. It is expected to see some
autophagy in control tumors characterized by ULK1 and activated p-ULK1 and p-AMPK
(Figure 8B). Tumors are often subjected to anoxic environments with low nutrient availability

and thus upregulate autophagy in order to sustain baseline function. Tumor treatment with
BC194 resulted in noticeable increases in ULK1, p-ULK1, and p-AMPK staining (Figure 8B).
This suggests that TARS enzyme activity works to prevent the initiation of autophagy and the
formation of active, phosphorylated ULK1 and AMPK. The proposed mechanism suggests that
TARS acts directly on AMPK to prevent activation of the ULK1 complex (Figure 3). The
proposed mechanism also predicts that TARS acts directly on the ULK1 complex to promote its
inactivation and dissociation (Figure 3). Increased levels of positive autophagy markers p-ULK
and p-AMPK with BC194 treatment support the hypothesis that blocking TARS signaling
increases markers of autophagy within tumors in a mouse model of ovarian cancer.
A future direction for this study is understanding the mechanism by which TARS
interacts with autophagy proteins. The interaction of TARS with the positive autophagy protein
ULK1 can be determined by subjecting purified ULK1 to an aminoacylation reaction with
purified TARS. The products of the reaction can then be separated by SDS/PAGE and analyzed
via mass spectroscopy to determine the mechanism of TARS/ULK1 interaction. Understanding
this interaction will give insights into how ULK1 can be modified to alter the rate of autophagy
within cancer cells. ULK1 is post-translationally acetylated and stimulated by the
acetyltransferase TIP60 to induce autophagy (Narita, Weinert, & Choudhary, 2019). TARS may
be catalyzing the threonylation and inactivation of ULK1 in order to inhibit autophagy. Further
studies with the goal of identifying this potential new autophagy signaling mechanism are
necessary in order to understand the greater significance of the observed results.
The results of this study as well as future studies investigating non-canonical functions of
ARS enzymes have the capacity to elucidate a potential new target in chemotherapeutic
intervention. Borrelidin analogues with decreased cytotoxicity have been biosynthetically
engineered for the purpose of anti-angiogenic use in cancer therapy (Wilkinson et al., 2006).

Drugs targeting TARS also have the potential to be utilized as autophagy regulators,
supplementing standard chemotherapeutic treatment regimens. Overall, this study used a
combination of in vitro and in vivo experiments to show that TARS inhibits the process of
autophagy within ovarian cancer cells. This project has led to a better understanding of where
TARS fits into the autophagic process and has the potential to affect the future approach to
treatment of ovarian cancer.
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